89bio to present 48-week data from enliven phase 2b pegozafermin trial in metabolic dysfunction-associated steatohepatitis (mash) at easl international liver congress

-poster presentation selected for the easl poster tour, a dedicated discussion session- -poster presentation selected for the easl poster tour, a dedicated discussion session-

ETNB Ratings Summary

ETNB Quant Ranking